The Wayback Machine - https://web.archive.org/web/20160203181709/https://en.wikipedia.org/wiki/TGBA01AD

TGBA01AD

From Wikipedia, the free encyclopedia
Jump to: navigation, search
TGBA01AD
Clinical data
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 17%[1]
Biological half-life 4 hours[2]

TGBA01AD is a serotonin reuptake inhibitor, 5-HT1A and 5-HT1D receptor agonist, and 5-HT2 receptor antagonist which is under development by Fabre-Kramer for the treatment of major depressive disorder.[1] [2] As of May 2015, the Fabre-Kramer website lists TGBA01AD as being in phase II clinical trials.[2]

See also[edit]

References[edit]

External links[edit]



Navigation menu

Personal tools

Namespaces

Variants

More

Languages

Morty Proxy This is a proxified and sanitized view of the page, visit original site.